Skip to main content

  • Check Out the Summer 2026 UM Ventures, Baltimore Newsletter

    The quarterly newsletter provides resources for UMB’s innovators as well as updates on UMB’s tech transfer and commercialization efforts.

    Read more

  • University System of Maryland Momentum Fund Invests in Alchemity

    The University of Maryland, College Park startup is transforming underutilized wasted resources and greenhouse gases into sustainable aircraft fuel for commercial airlines.

    Read more

  • GEn1e Lifesciences Granted Orphan Drug and Rare Pediatric Disease Designations

    This imporant milestones will support advancement of  GEn1E's second oral novel small molecule.

    Read more.

  • Secretome Therapeutics Closes $30M Series A

    The financing will support the continued advancement of STM-01, Secretome’s lead neonatal cardiac progenitor cell therapy, toward planned pivotal Phase 3 development in Duchenne muscular dystrophy-associated cardiomyopathy.

    Read more

  • Protaryx Medical Receives FDA 510(k) Clearance for Its Breakthrough Transseptal Puncture Device

    This milestone represents a significant advancement for the UMB startup's mission to redefine safe, efficient, and reproducible left heart access for cardiac interventions, enabling broader adoption and improved delivery of minimally invasive...

    Read the release

  • CoapTech Announces Inital Close of Series B

    Led by Good Growth Capital, with participation from UM Ventures, Baltimore and the Maryland Momentum Fund, the round will support commercial expansion of CoapTech’s PUMA System™. 

    Read more

  • Irazú Oncology Secures Bridge Funding, Expands Leadership Team and Facilities

    The UMB startup, which is developing next-generation cancer immunotherapies, is working to accelerate investigational new drug (IND) -enabling studies for its lead candidate and support preparations for future clinical development.

    Read more

  • Protaryx Medical Successfully Completes First-in-Human Study

    Co-founded by Dr. James Gammie, co-founder and inventor for Harpoon Medical, Protaryx is developing a device for left atrial access in transcatheter cardiac procedures.

    Read More

Search our portfolio:

TechnologiesCompanies

Recent News

More News

Spotlight on...

UM Ventures has launched a series of initiatives for the Center for Maryland Advanced Ventures, including:

NEW ACCELERATOR: Trajectory Next
Trajectory Next is a 12-week post-accelerator program for digital health, bio-health, and life sciences startups.

The Baltimore Fund
The Baltimore Fund provides financial incentives to companies affiliated with Maryland Public Higher Education Institutions to locate in a network of innovation centers in Baltimore City.

The UMCP Fischell Institute
The UMCP Fischell Institute for Biomedical Devices is opening a satellite location at UMB to accelerate the development of innovative medical devices.

Maryland Momentum Fund
The University System of Maryland created the Maryland Momentum Fund, a $25 million early-stage investment program investing in USM-affiliated companies. The Maryland Momentum Fund is staffed by UM Ventures.

University of Maryland, Baltimore Institute for Clinical and Translational Research
The University of Maryland, Baltimore Institute for Clinical and Translational Research (ICTR) is pleased to announce the first round of UMB ICTR Accelerated Translational Incubator Pilot (ATIP) Grant funding opportunities for 2018-2019.

VIEW MORE

University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More